Cytos inflammation, infectious news

Cytos said it is winding down key operational activities, particularly related to development and manufacturing of CYT003, and has completed a mass dismissal of 24 employees, effective July 31. Arthur Krieg, Yamo Deniz and Paul Brooke will step down as directors, leaving four remaining board members. The company is also seeking to engage in discussions with parties interested in Cytos' virus-like particle (VLP) B cell vaccines platform and ongoing preclinical development programs based on the platform. ...